Effects of once-daily versus twice-daily darunavir/ritonavir on lipid parameters at week 48 in treatment-experienced, HIV-1-infected patients with no darunavir resistance-associated mutations (RAMs) in the ODIN study

被引：0
|
作者：
Arribas, J. [1 ]
Arathoon, E. [2 ]
Gonsalez, C. R. [3 ]
Latiff, G. H. [4 ]
Van De Casteele, T. [5 ]
De Doncker, P. [5 ]
De La Rosa, G. [6 ]
Spinosa-Guzman, S. [5 ]
机构：
[1] Hosp Univ La Paz, IdiPAZ, Madrid, Spain
[2] Clin Familiar Luis Angel Garcia, Guatemala City, Guatemala
[3] Univ Sao Paulo, Hosp Clin, Fac Med, Pinheiros, Brazil
[4] Maxwell Ctr, Durban, South Africa
[5] Tibotec BVBA, Beerse, Belgium
[6] Tibotec Therapeut, Titusville, NJ USA
来源：
ANTIVIRAL THERAPY | 2010年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：A59 / A60
页数：2
相关论文
共 50 条
  • [1] Effects of once-daily versus twice-daily darunavir/ritonavir on lipid parameters at week 48 in treatment-experienced, HIV-1-infected patients with no darunavir resistance-associated mutations (RAMs) in the ODIN study
    Arribas, J.
    Arathoon, E.
    Gonsalez, C. R.
    Latiff, G. H.
    Van De Casteele, T.
    De Doncker, P.
    De La Rosa, G.
    Spinosa-Guzman, S.
    ANTIVIRAL THERAPY, 2010, 15 (08) : A59 - A60
  • [2] Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients
    Cahn, Pedro
    Fourie, Jan
    Grinsztejn, Beatriz
    Hodder, Sally
    Molina, Jean-Michel
    Ruxrungtham, Kiat
    Workman, Cassy
    Van De Casteele, Tom
    De Doncker, Piet
    Lathouwers, Erkki
    Tomaka, Frank
    AIDS, 2011, 25 (07) : 929 - 939
  • [3] Efficacy and Safety at 48 weeks of Once-daily (qd) versus Twice-daily (bid) Darunavir/ritonavir (DRV/r) in Treatment-experienced HIV-1-infected Patients with no DRV Resistance-Associated Mutations (RAMs) in the ODIN trial
    Lazzarin, A.
    Cahn, P.
    Fourie, J.
    Grinsztejn, B.
    Hodder, S.
    Molina, J. -M.
    Ruxrungtham, K.
    Workman, C.
    Garau, M.
    De Doncker, P.
    INFECTION, 2010, 38 : 61 - 62
  • [4] Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial
    Sension, M.
    Cahn, P.
    Domingo, P.
    Hodder, S.
    Opsomer, M.
    Lathouwers, E.
    Van de Casteele, T.
    Tomaka, F.
    HIV MEDICINE, 2013, 14 (07) : 437 - 444
  • [5] Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir
    De Meyer, Sandra M. J.
    Spinosa-Guzman, Sabrina
    Vangeneugden, Tony J.
    de Bethune, Marie-Pierre
    Miralles, G. Diego
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 49 (02) : 179 - 182
  • [6] Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment
    Rolle, Charlotte-Paige
    Marquez, Omar
    Nguyen, Vu
    Hinestrosa, Federico
    DeJesus, Edwin
    INTERNATIONAL JOURNAL OF STD & AIDS, 2020, 31 (10) : 958 - 966
  • [7] Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
    Ortiz, Roberto
    DeJesus, Edwin
    Khanlou, Homayoon
    Voronin, Evgeniy
    van Lunzen, Jan
    Andrade-Villanueva, Jaime
    Fourie, Jan
    De Meyer, Sandra
    De Pauw, Martine
    Lefebvre, Eric
    Vangeneugden, Tony
    Spinosa-Guzman, Sabrina
    AIDS, 2008, 22 (12) : 1389 - 1397
  • [8] Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naive HIV-1-infected ARTEMIS patients at week 96
    Baraldi, E.
    Morales-Ramirez, J.
    Schneider, S.
    Stoehr, A.
    Orani, A.
    Van De Casteele, T.
    Lavreys, L.
    Hill, A.
    ANTIVIRAL THERAPY, 2009, 14 (07) : A55 - A56
  • [9] Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS
    Arathoon, E.
    Schneider, S.
    Baraldi, E.
    Lim, P. L.
    Opravil, M.
    Van De Casteele, T.
    Lavreys, L.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2013, 24 (01) : 12 - 17
  • [10] Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals
    Soria, A
    Gianotti, N
    Cernuschi, M
    Lazzarin, A
    MICROBIOLOGICA, 2004, 27 (01): : 11 - 15
12345